Trials
2 active
5 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The starting dose of QL0911 is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.…”In the company’s words, NCT07455006 on ClinicalTrials.gov
- Tested for
- Thrombocytopenia, Immune, Cancer Treatment-Induced Thrombocytopenia
- Main trialPhase 3
- “The purpose of this study is to evaluate efficacy and of safety QL0911 in the treatment of thrombocytopenia in pediatric patients with previously treated chronic ITP.”In the company’s words, NCT07455006 on ClinicalTrials.gov
Other drugs for Thrombocytopenia, Immune
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
- MezagitamabTakeda · Phase 3
Coming up2
- 30 Apr 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 10 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 10 Dec 2027 | Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients | |
| Phase 2/3Recruiting | 30 Apr 2027 | QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia | |
| Phase 3Completed | 13 Dec 2021 | Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia | |
| Phase 2/3Completed | 10 Sep 2021 | Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia | |
| Phase 2/3Completed | 20 Feb 2024 | Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026